Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2011, Vol. 33 ›› Issue (4): 393-396.doi: 10.3881/j.issn.1000-503X.2011.04.009

• Abstracts • Previous Articles     Next Articles

Expressions of Receptor Tyrosine Kinases mRNA and Protein in Carcinoma of Bladder

WEN Jin, LI Hanzhong, JI Zhigang, YAN Weigang, SHI Bingbing   

  1. Department of Urology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China
  • Received:2011-01-21 Revised:2011-09-05 Online:2011-08-01 Published:2011-08-01
  • Contact: LI Han-zhong E-mail:ljjxmc@163.com
  • Supported by:

    Supported by the Natural Science Foundation of Beijing (7102128) and The Youth Foundation of PUMCH in 2010

Abstract: Objective To detect the expressions of receptor tyrosine kinases (RTKs) mRNA and protein and to explore potentially promising tumor markers and conceivable drug target in bladder cancer. Methods The expressions of RTKs mRNA and protein in tissue from invasive urothelial carcinoma of the bladder were examined by real-time quantitative PCR array and cytokine antibody array, with normal bladder tissue as control. The Results were analyzed using bioinformatic approaches. Results The expressions of TGFA, STAB1, SERPINE1, ANGPT2, SPINK5, ANGPTL1, PROK1, MDK, CXCL9, GRN, RUNX1, VEGFA, and TGFB1 were obviously upregulated in bladder cancer tissue, while those of EDIL3, PTN, CCL2, PDGFD, FGF13, KITLG, FGF2, SERPINF1, and TNF were downregulated. ALK, Btk, EphB2, ErbB4, PDGFR-α, ROS, Tie-2, Tyk2, and VEGFR3 were over-expressed in bladder cancer, while FRK, Fyn, IGF-IR, Insulin R, Itk, JAK1, JAK3, and LCK were low-expressed.Conclusion Vascular endothelial growth factor/platelet-derived growth factor-targeted therapies may play an active role in treating carcinoma of bladder."

Key words: real-time quantitative PCR, cytokine antibody array, receptor tyrosine kinases, carcinoma of bladder

CLC Number: